Taro Pharmaceutical Industries Stock Total Debt
| TARODelisted Stock | USD 42.97 0.00 0.00% |
Taro Pharmaceutical Industries fundamentals help investors to digest information that contributes to Taro Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Taro Stock. The fundamental analysis module provides a way to measure Taro Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Taro Pharmaceutical stock.
Taro |
Taro Pharmaceutical Industries Company Total Debt Analysis
Taro Pharmaceutical's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Taro Pharmaceutical Total Debt | 369.06 M |
Most of Taro Pharmaceutical's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Taro Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Taro Pharmaceutical Industries has a Total Debt of 369.06 M. This is 86.59% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 93.06% higher than that of the company.
Taro Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Taro Pharmaceutical's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Taro Pharmaceutical could also be used in its relative valuation, which is a method of valuing Taro Pharmaceutical by comparing valuation metrics of similar companies.Taro Pharmaceutical is currently under evaluation in total debt category among its peers.
Taro Fundamentals
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 735.67 M | |||
| Shares Outstanding | 37.58 M | |||
| Shares Owned By Insiders | 78.48 % | |||
| Shares Owned By Institutions | 13.06 % | |||
| Number Of Shares Shorted | 73.56 K | |||
| Price To Earning | 14.57 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 2.59 X | |||
| Revenue | 629.18 M | |||
| Gross Profit | 293.13 M | |||
| EBITDA | 52.6 M | |||
| Net Income | 53.87 M | |||
| Cash And Equivalents | 806.25 M | |||
| Cash Per Share | 21.45 X | |||
| Total Debt | 369.06 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 3.60 X | |||
| Book Value Per Share | 47.70 X | |||
| Cash Flow From Operations | 132.39 M | |||
| Short Ratio | 3.20 X | |||
| Earnings Per Share | 1.43 X | |||
| Target Price | 43.0 | |||
| Number Of Employees | 24 | |||
| Beta | 0.56 | |||
| Market Capitalization | 1.62 B | |||
| Total Asset | 2.16 B | |||
| Retained Earnings | 2.41 B | |||
| Working Capital | 950.88 M | |||
| Current Asset | 1.88 B | |||
| Current Liabilities | 245.46 M | |||
| Net Asset | 2.16 B |
About Taro Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Taro Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Taro Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Taro Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Taro Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taro Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taro Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Taro Stock
| 0.9 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.87 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.85 | HYMTF | Hyundai Motor | PairCorr |
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.78 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Taro Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taro Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taro Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taro Pharmaceutical Industries to buy it.
The correlation of Taro Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taro Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taro Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taro Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Taro Stock
If you are still planning to invest in Taro Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taro Pharmaceutical's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |